NextCure, Inc.

NXTC Healthcare Biotechnology

In the quarter to June 2026, EPS grew 75.2% and free cash flow grew 57.2%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

6.24 0.64 −9.30%
Market cap
$31.5M
P/E
0.0×
Fwd P/E
−2.4×
Dividend yield
—
F-score
n/a
Altman Z
14.11
Beneish M
n/a
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
ROE

+8 more TTM periods

(116.91%) (111.23%) (132.40%) (195.22%)
ROA
(89.28%) (85.23%) (104.01%) (121.60%)
ROIC
0.00% 0.00% 0.00% 0.00%
Return on Tangible Assets
(229.45%) (153.19%) (196.35%) (265.10%)
Average Days of Receivables
— — — —
Free Cash Flow per Share
(18.29) (17.45) (9.54) (6.97)
Free Cash Flow
(48.94) (49.61) (49.98) (36.98)
Other line items

Show all line items

Columns are period end dates